0GQU.LSE

Active Biotech AB

0GQU.LSE, UK

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. The company is developing Naptumomab, an anti-cancer immunotherapy that is in Phase Ib/II clinical trial to treat patients with advanced solid tumors; and Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. It is also developing Laquinimod, a small molecule immuno-modulator to treat inflammatory eye disorders, non-infectious uveitis, and wet age-related macular degeneration (wAMD). The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.

https://www.activebiotech.com

Stock Price

SEK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2021-06-30)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of Active Biotech AB

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2021-06-30

EPS Actual

-0.0578

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2021-06-30)

Deep Value
Weak Deep Value(0)
Defensive
Cyclical / Risky(3)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(4)
Quality
Low Quality Business(0)
Value
Overpriced(0)

Income Statement

(Last Updated 2021-06-30)

Revenue

SEK 0

Cost Of Revenue

SEK 0

Gross Profit

SEK 0

Operating Expenses

SEK 0

Operating Income

SEK 0

Interest Expense

SEK 0

Pretax Income

SEK 0

Net Income

SEK 0

Income Tax Expense

SEK 0

EBITDA

SEK 0

Total Other Income Expense Net

SEK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2021-06-30)

Cash

SEK 0

Short Term Investments

SEK 0

Receivables

SEK 0

Inventories

SEK 0

Total Current Assets

SEK 0

Property Plant Equipment

SEK 0

Total Assets

SEK 0

Payables

SEK 0

Short Term Debt

SEK 0

Long Term Debt

SEK 0

Total Liabilities

SEK 0

Equity

SEK 0

Trend

Cash Flow

(Last Updated 2021-06-30)

Net Income

SEK 0

Depreciation

SEK 0

Change In Working Capital

SEK 0

Cash From Operations

SEK 0

Capital Expenditures

SEK 0

Cash From Investing

SEK 0

Cash From Financing

SEK 0

Net Change In Cash

SEK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.